MedTrace Logo

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

NCT00440765 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 331

Last updated 2014-01-14

No results posted yet for this study

Summary

The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.

Conditions

Interventions

DRUG

bortezomib

dose as determined (observational study) by treating physician

Sponsors & Collaborators

  • Janssen-Cilag B.V.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag B.V. Clinical Trial · Janssen-Cilag B.V.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440765 on ClinicalTrials.gov